Overview

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

Status:
Recruiting

Trial end date:
2025-06-02

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Antibodies, Monoclonal
Etanercept